Market Place
Sourcing Support
Aravive, Inc. to Delist from The Nasdaq Stock Market
17 Jan 2024 //
GLOBENEWSWIRE
Aravive, weeks from liquidation, lays off 70% of its staff
22 Aug 2023 //
FIERCE BIOTECH
Phase 3 cancer flop blows hole in plans of cast-strapped Aravive
03 Aug 2023 //
FIERCE BIOTECH
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept
02 Aug 2023 //
GLOBENEWSWIRE
Aravive to Present Updated Clinical Data from Batiraxcept Trials
28 Jul 2023 //
GLOBENEWSWIRE
Aravive to Participate in William Blair`s Innovator Series
14 Jul 2023 //
GLOBENEWSWIRE
Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)
13 Jun 2023 //
GLOBENEWSWIRE
Aravive To Participate in the Jefferies Global Healthcare Conference
05 Jun 2023 //
GLOBENEWSWIRE
Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcep
25 May 2023 //
GLOBENEWSWIRE
Aravive Announces Ph3 Trial Design for Batiraxcept in Renal Cell Carcinoma
16 May 2023 //
GLOBENEWSWIRE
Aravive Reports 1Q 2023 Financial Results and Provides Corporate Updates
10 May 2023 //
GLOBENEWSWIRE
Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept
08 May 2023 //
GLOBENEWSWIRE
Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting
26 Apr 2023 //
GLOBENEWSWIRE
Aravive Appoints Carolina Petrini as Chief Commercial Officer
11 Apr 2023 //
GLOBENEWSWIRE
Aravive Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
Aravive Announces FDA Orphan Drug Designation Granted to Batiraxcept
28 Feb 2023 //
GLOBENEWSWIRE
Aravive to Present Positive Data from P1b Trial of Batiraxcept with Cabozantinib
13 Feb 2023 //
GLOBENEWSWIRE
Aravive Announces Complete Enrollment in PIII AXLerate-OC Trial
04 Jan 2023 //
GLOBENEWSWIRE
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
29 Nov 2022 //
GLOBENEWSWIRE
Aravive To Participate in Piper’s 34th Annual Healthcare Conference
21 Nov 2022 //
GLOBENEWSWIRE
Aravive Reports 3Q 2022 Financial Results and Provides Corporate Updates
10 Nov 2022 //
GLOBENEWSWIRE
Aravive Receives Third Development Milestone from 3D Medicines
10 Oct 2022 //
GLOBENEWSWIRE
Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference
26 Sep 2022 //
GLOBENEWSWIRE
Aravive to Participate in H.C. Wainwright 24th Annual GIC
06 Sep 2022 //
GLOBENEWSWIRE
Aravive Reports Q2 2022 Rusult and Provides Corporate Updates
11 Aug 2022 //
GLOBENEWSWIRE
Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer
05 Jul 2022 //
GLOBENEWSWIRE
Aravive Appoints Rudy Howard as Chief Financial Officer
03 Jun 2022 //
GLOBENEWSWIRE
Aravive Presents Updated Clinical Data at ASCO on Batiraxcept in ccRCC
26 May 2022 //
GLOBENEWSWIRE
Aravive to Participate in H.C. Wainwright Global Investment Conference
17 May 2022 //
GLOBENEWSWIRE
Aravive to Host Key Opinion Leader Symposium on May 11, 2022
05 May 2022 //
GLOBENEWSWIRE
Aravive Announces Poster Presentations at the 2022 ASCO Annual Meeting
29 Apr 2022 //
GLOBENEWSWIRE
Aravive Closes $10M Registered Direct Offering Under Nasdaq Rules
01 Apr 2022 //
GLOBENEWSWIRE
Aravive Reports Fourth Quarter and Full Year 2021 Financial Results
31 Mar 2022 //
GLOBENEWSWIRE
Aravive Announces $10M Registered Direct Offering Priced At-The-Market
30 Mar 2022 //
GLOBENEWSWIRE
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
22 Mar 2022 //
GLOBENEWSWIRE
Aravive to Participate In-Person at 34th Annual ROTH Conference
07 Mar 2022 //
GLOBENEWSWIRE
Aravive Announces Positive Updated Data from Phase 1b Study of Batiraxcept
03 Mar 2022 //
GLOBENEWSWIRE
Aravive to Present Updated Modeling Data from Batiraxcept Trials at the AACR
02 Mar 2022 //
GLOBENEWSWIRE
Aravive Begins Dosing in Phase 2 Study of Batiraxcept in ccRCC
31 Jan 2022 //
GLOBENEWSWIRE
Aravive Announces $10M Investment by Eshelman Ventures; & more
03 Jan 2022 //
GLOBENEWSWIRE
Aravive to Present New Preliminary Data from Phase 1b Trial Evaluating AVB-500
01 Oct 2021 //
GLOBENEWSWIRE
Aravive to Present at Fireside Chat at Cantor Fitzgerald Healthcare Conference
16 Sep 2021 //
GLOBENEWSWIRE
Aravive Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
Aravive Achieves Second Development Milestone from 3D Medicines
15 Jul 2021 //
GLOBE NEWSWIRE
Aravive to Participate in Fireside Chat at 2021 William Blair Focus Conference
07 Jul 2021 //
GLOBENEWSWIRE
Aravive Announces Positive Data of AVB-500 in Combination with Cabozantinib
24 Jun 2021 //
GLOBENEWSWIRE
Aravive Announces First Patient Dosed in Ph 3 Trial Evaluating AVB-500
27 Apr 2021 //
GLOBENEWSWIRE
Aravive to Present Phase 1b Data Evaluating AVB-500 in Platinum Ovarian at 2021
12 Mar 2021 //
GLOBENEWSWIRE
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500
08 Mar 2021 //
BIOSPACE
Aravive Appoints Reshma Rangwala, M.D., Ph.D., as Chief Medical Officer
15 Sep 2020 //
GLOBENEWSWIRE
Aravive Strengthens Leadership Team with Appointment of Key Industry Veterans
27 Aug 2020 //
GLOBENEWSWIRE
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
23 Jul 2020 //
GLOBENEWSWIRE
WuXi Biologics & Aravive Form Strategic Collaboration to Develop High-Affinity
30 Apr 2020 //
PRNEWSWIRE
Aravive Announces Initiation of Investigator-Sponsored Ph 1/2 Study of AVB-500
24 Mar 2020 //
GLOBENEWSWIRE
Aravive Announces Dose Escalation of AVB-500 in Platinum Ovarian Phase 1b Trial
18 Feb 2020 //
GLOBENEWSWIRE
Aravive Receives IND Clearance for Phase 1b/Phase 2 Clinical Trial of AVB-500
13 Jan 2020 //
PRESS RELEASE
Aravive Initiates a Ph 2a Clinical Trial of Patients with Kidney Fibrosis
20 Dec 2019 //
PRESS RELEASE
FDA Grants Fast Track Designation to Aravive Biologics’ AVB-S6-500
20 Aug 2018 //
R&DMAG
Versartis, Aravive enter into merger agreement
04 Jun 2018 //
BIOSPECTRUM
Aravive’s CEO exit, Fierce 15 winner reveals near-death Versartis merger deal
04 Jun 2018 //
FIERCE BIOTECH
